A comparative analysis of fluoxetine and amitriptyline in depression: assessing effectiveness and adherence in a rural hospital setting
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20252577Keywords:
Depression, Fluoxetine, Amitriptyline, Adherence, MMAS-4, HAM-D-17Abstract
Background: Fluoxetine and amitriptyline are commonly prescribed antidepressants. However, the superior option in terms of effectiveness and adherence remains unclear. Medication non-adherence significantly impacts treatment outcomes. This study aims to compare the two drugs in terms of effectiveness and adherence, and to assess their correlation.
Methods: This is a single-centered, prospective observational study, conducted in the psychiatric outpatient department (OPD) of the Government Medical College and Hospital, Nagapattinam, over six months (23 July 2024 to 22 January 2025). It included 126 patients newly diagnosed with depression. Patients receiving either fluoxetine or amitriptyline were enrolled. Effectiveness was measured using the 17-item Hamilton depression rating scale (HAM-D), calculating score reduction from baseline to endpoint. The four-item Morisky scale (MMAS-4) was applied to assess the medication adherence of the participants. Data were analysed with statistical package for the social sciences (SPSS) version 24, applying descriptive analysis, independent t-test and Pearson correlation as appropriate.
Results: Depression was more prevalent among women. Most participants were married and unemployed. Fluoxetine showed a greater mean reduction in HAM-D scores compared to amitriptyline. It also demonstrated higher medication adherence. A statistically significant positive correlation between effectiveness and adherence was observed for both drugs.
Conclusions: Better clinical outcomes were associated with higher medication adherence. Fluoxetine was superior to amitriptyline in both effectiveness and adherence. These findings highlight the importance of adherence in improving depression treatment outcomes.
Metrics
References
Vashisht E, Singh G, Vats V, Dhiman A, Singla C. An update on epidemiology of depression: a major concern. Ann Rom Soc Cell Biol. 2021:616-24.
Sandanapitchai V, Ramasamy S, Pichai E. Prospective study to evaluate the efficacy of fluoxetine in comparison with amitriptyline in patients with depression. Int J Basic Clin Pharmacol. 2016;5(6):2552-5. DOI: https://doi.org/10.18203/2319-2003.ijbcp20164122
Iyer K, Khan ZA. Depression – a review. Res J Recent Sci. 2012;1(4):79-87.
Lexicomp. Fluoxetine: drug information. 2024. Available at: https://online.lexi.com/lco/action/doc/ retrieve/docid/multinat_f/4669729. Accessed on 28 October 2024.
Lexicomp. Amitriptyline: drug information. Lexicomp Online. Wolters Kluwer Clinical Drug Information, Inc. 2024. Available at: https://online. lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668901. Accessed on 29 October 2024.
Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26(3):155-9. DOI: https://doi.org/10.5001/omj.2011.38
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence and long-term predictive validity of blood pressure control. Med Care. 1986;24(1):67-74. DOI: https://doi.org/10.1097/00005650-198601000-00007
Morisky DE, Malotte CK, Choi P, Etrata R, Davidson P, Rigler S, et al. A patient education program to improve rate with antituberculosis drug regimens. Health Educ Q. 1990;17:253-68. DOI: https://doi.org/10.1177/109019819001700303
Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: final response. J Clin Epidemiol. 2011;64(3):262-3. DOI: https://doi.org/10.1016/j.jclinepi.2010.09.010
Arvind BA, Gururaj G, Loganathan S, Booth A, Sathyanarayana Rao TS, Kokane AM, et al. Prevalence and socioeconomic impact of depressive disorders in India: multisite population-based cross-sectional study. BMJ Open. 2019;9(6):e027250. DOI: https://doi.org/10.1136/bmjopen-2018-027250
Zhang B, Li J. Gender and marital status differences in depressive symptoms among elderly adults: The roles of family support and friend support. Aging Ment Health. 2011;15(7):844-54. DOI: https://doi.org/10.1080/13607863.2011.569481
Arias de la Torre J, Vilagut G, Ronaldson A, Serrano-Blanco A, Fernandez A, Dregan A, et al. Prevalence and age patterns of depression in the United Kingdom: a population-based study. J Affect Disord. 2021;279:164-72. DOI: https://doi.org/10.1016/j.jad.2020.09.129
Rizvi SJ, Cyriac A, Grima E, Tan M, Lin P, Gallaugher LA, et al. Depression and employment status in primary and tertiary care settings. Can J Psychiatry. 2015;60(1):14-22. DOI: https://doi.org/10.1177/070674371506000105
Zhao L, Zhang K, Gao Y, Wu J, Wang Y, Chen Y, et al. The relationship between gender, marital status and depression among Chinese middle-aged and older people: mediation by subjective well-being and moderation by degree of digitization. Front Psychol. 2022;13:923597. DOI: https://doi.org/10.3389/fpsyg.2022.923597
Laakmann G, Blaschke D, Engel R, Jahnke S, Wittchen HU, Essau C. Fluoxetine vs amitriptyline in the treatment of depressed out-patients. Br J Psychiatry. 1988;153(3):64-8. DOI: https://doi.org/10.1192/S0007125000297316
Hosák L, Tůma I, Hanuš H, Libiger J, Beran V. Costs and outcomes of use of amitriptyline, citalopram, and fluoxetine in major depression: exploratory study. Acta Med (Hradec Králové). 2000;43(4):133-6. DOI: https://doi.org/10.14712/18059694.2019.127
Lader M. Fluoxetine efficacy vs comparative drugs: an overview. Br J Psychiatry. 1988;153(3):51-8. DOI: https://doi.org/10.1192/S0007125000297298
Demyttenaere K, Mesters P, Boulanger B, Despiegel N, Dewe W. Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. J Affect Disord. 2001;65(3):243-52. DOI: https://doi.org/10.1016/S0165-0327(00)00225-1
Downloads
Published
How to Cite
Issue
Section
